Search

Displaying results 1491 - 1500 of 7498 in total
  1. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    [A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 [A183062] for the treatment of narcolepsy with or without cataplexy.

  2. Drug

    Amdinocillin

    go.drugbank.com/drugs/DB01163
    ApprovedInvestigationalWithdrawn

    Amdinocillin is not available in the United States.

  3. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration

  4. Drug

    Urea C-14

    go.drugbank.com/drugs/DB09513
    ApprovedInvestigational

    To detect H. pylori, urea labeled with 14C is swallowed by the patient. … Both forms can be used within the Urea Breath Test, however some may prefer 13C as it is non-radioactive compared to 14C, which may be preferable in pregnant women and children.

  5. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  6. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome

  7. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not … As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically

  8. Drug

    Pipobroman

    go.drugbank.com/drugs/DB00236
    Approved

    An antineoplastic agent that acts by alkylation.

    Synonyms: N,N-bis-(3-bromopropionyl)-piperazine
  9. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. … On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.

  10. Drug

    Ertapenem

    go.drugbank.com/drugs/DB00303
    ApprovedInvestigational

    [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. … Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.[L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002.